Vimal Mehta - Insider Trading Tracker

Introduction

This page provides a comprehensive analysis of the known insider trading history of Vimal Mehta. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

Companies with Reported Insider Positions

The SEC filings indicate Vimal Mehta has reported holdings or trades in the following companies:

How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Vimal Mehta. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases BTAI / BioXcel Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in BTAI / BioXcel Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date	Ticker	Insider	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Max	Price at Max	Max Profit ($)	Max Return (%)
2019-08-16	BTAI	Mehta Vimal	974	8.8900	61	142.2400	8,659	341	64.63	-4,780	-55.21
2019-08-15	BTAI	Mehta Vimal	2,625	8.6700	164	138.7200	22,759
2019-08-14	BTAI	Mehta Vimal	358	8.4400	22	135.0400	3,022
2019-08-13	BTAI	Mehta Vimal	1,000	8.7500	62	140.0000	8,750
2018-12-14	BTAI	Mehta Vimal	800	4.2700	50	68.3200	3,416
2018-12-14	BTAI	Mehta Vimal	200	4.3200	12	69.1200	864
2018-12-14	BTAI	Mehta Vimal	500	4.4800	31	71.6800	2,240
2018-12-14	BTAI	Mehta Vimal	400	4.4900	25	71.8400	1,796
2018-12-14	BTAI	Mehta Vimal	100	4.5000	6	72.0000	450
2018-12-04	BTAI	Mehta Vimal	500	5.0900	31	81.4400	2,545
2018-12-04	BTAI	Mehta Vimal	500	5.1500	31	82.4000	2,575
2018-12-03	BTAI	Mehta Vimal	200	5.1000	12	81.6000	1,020
2018-12-03	BTAI	Mehta Vimal	100	5.1300	6	82.0800	513
2018-12-03	BTAI	Mehta Vimal	100	5.1400	6	82.2400	514
2018-12-03	BTAI	Mehta Vimal	100	5.1800	6	82.8800	518
2018-12-03	BTAI	Mehta Vimal	500	5.2000	31	83.2000	2,600
2018-11-30	BTAI	Mehta Vimal	300	5.0400	19	80.6400	1,512
2018-11-30	BTAI	Mehta Vimal	300	5.0500	19	80.8000	1,515
2018-11-30	BTAI	Mehta Vimal	100	5.1700	6	82.7200	517
2018-11-30	BTAI	Mehta Vimal	300	5.2000	19	83.2000	1,560
2018-03-12	BTAI	Mehta Vimal	2,000	11.0000	125	176.0000	22,000

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

Insider Sales BTAI / BioXcel Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in BTAI / BioXcel Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date	Ticker	Insider	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Min	Price at Min	Max Loss Avoided ($)	Max Loss Avoided (%)
2024-06-05	BTAI	Mehta Vimal	283,122		17,695			247	0.1650
2024-06-05	BTAI	Mehta Vimal	126,014	1.5841	7,876	25.3456	199,619
2024-06-04	BTAI	Mehta Vimal	609,221		38,076
2024-06-04	BTAI	Mehta Vimal	283,123		17,695
2024-06-04	BTAI	Mehta Vimal	126,014	1.6309	7,876	26.0944	205,516

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

Insider Trading History

This table shows the complete list of insider trades made by Vimal Mehta as disclosed to the Securities Exchange Commission (SEC).